Selenium supplementation at 200 µg/day significantly reduces fasting plasma glucose levels in women with gestational diabetes mellitus (GDM).
Reduced incidence of newborn hyperbilirubinemia was observed with selenium supplementation.
Selenium did not significantly impact insulin resistance as measured by HOMA-IR or lipid profiles including total cholesterol, triglycerides, LDL-C, and HDL-C.
Current evidence draws from a limited number of randomized controlled trials, warranting cautious interpretation and need for further validation.
